Biomerieux SA
F:EYW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biomerieux SA
F:EYW
|
FR |
|
Aristocrat Leisure Ltd
ASX:ALL
|
AU |
|
Uniflex Technology Inc
TWSE:3321
|
TW |
|
C
|
Chugai Pharmaceutical Co Ltd
DUS:CUP
|
JP |
|
G
|
Glory Forever PCL
SET:GLORY
|
TH |
|
ArcelorMittal SA
NYSE:MT
|
LU |
|
Graphite One Inc
F:2JCA
|
CA |
|
G
|
Globe Life Inc
XMUN:TMJ
|
US |
|
B
|
Bristol-Myers Squibb Co
XMUN:BRM
|
US |
Intrinsic Value
Is EYW undervalued or overvalued?
See the intrinsic value estimate for 
Biomerieux SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Biomerieux Does
bioMérieux makes laboratory tests that help doctors and companies find microbes and understand whether a sample is safe. Its products include testing instruments, disposable reagents, software, and service contracts. In hospitals and public labs, these tests are used to identify infections and guide treatment decisions.
- Headquarters
- France FR
- Employees
- 14 894
- IPO date
- Jun 7, 2004
Biomerieux has no economic moat
Hospitals, laboratories and industrial customers can choose among competing diagnostic systems, and bioMérieux’s products do not become more valuable just because more customers use them. Its strong presence in some areas does not prevent rivals from competing for buyers or guarantee that customers will pay more for its name alone.
Read the full moat analysis
Earnings Waterfall
Biomerieux SA
The intrinsic value for Biomerieux SA (EYW) under the Base Case is hidden EUR.
Compared with the current market price of 206.421 EUR, the stock appears hidden.